Sawai’s Upsher-Smith Gets New Leadership Amid ‘Drastic Restructuring’
New CEO And President Appointed After Japanese Firm Records Impairment For US Unit
A major overhaul is in progress for Sawai’s Upsher-Smith business, after the Japanese parent company announced leadership changes and a “drastic restructuring” of the US unit in the wake of a significant impairment charge and a hefty annual operating loss that dragged down Sawai’s overall results.
You may also be interested in...
Sawai’s Q1 momentum spread into its overall first half financial results, with setbacks and risks in its dominant Japanese business and greener shoots for its formerly spluttering Upsher-Smith operation in the US.
Looking back over the second quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from April to June that include multiple first generic and biosimilar launches, some noteworthy executive moves, further preparation for biosimilar competition to Humira in the US, and a major European industry conference.
Looking back at recent company decisions to shift product strategy, restructure its US Upsher-Smith business and acquire manufacturing sites from a former domestic competitor, Sawai's president shares the breadth of the Japanese firm’s vision.